Education
About Us
Working with TipRanks
Follow Us
Hua Medicine Ltd. (HK:2552)
:2552
2552 Stock Chart & Stats
HK$3.29
-HK$0.05(-3.62%)
At close: 4:00 PM EST
HK$3.29
-HK$0.05(-3.62%)
Day’s Range― - ―
52-Week RangeHK$1.73 - HK$4.95
Previous CloseN/A
Volume1.46M
Average Volume (3M)6.34M
Market Cap
HK$3.03B
Enterprise ValueHK$2.05B
Total Cash (Recent Filing)HK$1.02B
Total Debt (Recent Filing)HK$271.05M
Price to Earnings (P/E)2.7
Beta1.24
Next Earnings
Mar 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.30
Shares Outstanding1,056,605,000
10 Day Avg. Volume6,422,209
30 Day Avg. Volume6,335,350
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-9.93
Price to Sales (P/S)5.26
P/FCF Ratio-3.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained 18.32% TTM revenue growth indicates expanding commercial traction for its diabetes therapies and strengthens the recurring sales base. Over the next 2–6 months this supports reinvestment in R&D and commercialization, validating product-market fit.
Manageable LeverageA debt-to-equity of 0.26 implies limited leverage, giving the company financial flexibility to fund operations, negotiate partnerships, or raise modest debt without severe solvency risk. This supports strategic moves while addressing cash burn over the medium term.
Commercialization And Partner Revenue MixRevenue sources from product sales, collaborations, milestones and licensing create diversified cash inflows. Structural mix reduces dependence on single channels, provides non-dilutive milestone or royalty upside and supports longer-term funding of pipeline development.
Bears Say
Negative Operating And Free Cash FlowOngoing negative operating and free cash flow indicate persistent cash burn that will likely require external financing or partnerships. Over 2–6 months this constrains discretionary spending, risks dilution or higher leverage, and limits independent scaling of commercialization.
Weak Core ProfitabilityNegative operating margins show the core business is not yet profitable and a one-time gain masks true performance. Structurally weak margins reduce ability to self-fund R&D and commercialization, forcing reliance on external capital absent meaningful margin improvement.
Low Return On EquityLow ROE reflects limited effectiveness in converting equity into profits, signaling operational or capital allocation inefficiencies. Over the medium term this can dampen investor confidence, raise the cost of new equity financing and pressure strategic flexibility.
Hua Medicine News
2552 FAQ
What was Hua Medicine Ltd.’s price range in the past 12 months?
Hua Medicine Ltd. lowest stock price was HK$1.73 and its highest was HK$4.95 in the past 12 months.
What is Hua Medicine Ltd.’s market cap?
Hua Medicine Ltd.’s market cap is HK$3.03B.
When is Hua Medicine Ltd.’s upcoming earnings report date?
Hua Medicine Ltd.’s upcoming earnings report date is Mar 26, 2026 which is in 30 days.
How were Hua Medicine Ltd.’s earnings last quarter?
Hua Medicine Ltd. released its earnings results on Aug 28, 2025. The company reported HK$1.301 earnings per share for the quarter, beating the consensus estimate of N/A by HK$1.301.
Is Hua Medicine Ltd. overvalued?
According to Wall Street analysts Hua Medicine Ltd.’s price is currently Overvalued.
Does Hua Medicine Ltd. pay dividends?
Hua Medicine Ltd. does not currently pay dividends.
What is Hua Medicine Ltd.’s EPS estimate?
Hua Medicine Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hua Medicine Ltd. have?
Hua Medicine Ltd. has 1,056,605,000 shares outstanding.
What happened to Hua Medicine Ltd.’s price movement after its last earnings report?
Hua Medicine Ltd. reported an EPS of HK$1.301 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of Hua Medicine Ltd.?
Currently, no hedge funds are holding shares in HK:2552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hua Medicine Ltd.
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.
Technical Analysis
Essex Bio-Technology
―
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―
China Shineway Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---